Essen

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Forrás

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· Forrás

• Toboroz

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· 3. fázis· Forrás

• Toboroz

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· 3. fázis· Forrás

• Toboroz

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· Forrás

• Toboroz

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· 3. fázis· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· Forrás

• Toboroz

  Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· 1/2. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· Forrás

• Toboroz

  Anifrolumab Malignancy and Serious Infections Study

  NCT07000110· Forrás

• Toboroz

  NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

  NCT06890273· Forrás

• Toboroz

  Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

  NCT06312644· Forrás

• Toboroz

  A Non-interventional, Prospective Study With Benralizumab

  NCT06422078· Forrás

• Fut, nem toboroz

  Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

  NCT06336330· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Toboroz

  AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  NCT06106945· 1/2. fázis· Forrás

• Toboroz

  PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

  NCT05573893· Forrás

• Fut, nem toboroz

  Retention Rate of Acalabrutinib in a Non-interventional Setting

  NCT05645172· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

  NCT03164616· 3. fázis· Forrás

• Fut, nem toboroz

  Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

  NCT01081951· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex4 toboroz
• Amiloidózis2 toboroz
• Lupus (SLE)2 toboroz
• Prosztatarák2 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Krónikus vesebetegség1 toboroz
• Méhtestrák1 toboroz
• Myasthenia gravis1 toboroz
• Neuromyelitis optica (NMOSD)1 toboroz
• Petefészekrák1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz
• Szívelégtelenség1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· Forrás

• Lezárult

  A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT05573464· 3. fázis· Forrás

• Toboroz

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· 2. fázis· Forrás

• Leállították

  Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

  NCT05006573· 3. fázis· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· Forrás

• Lezárult

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· 1/2. fázis· Forrás